Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIHealth services research, TreatmentClosed18 and overNCI, OtherCDR0000063648
NCCTG-934653, CAN-NCIC-CO12, CLB-9396, E-7293, NSABP-CI64, RTOG-9415, SWOG-9411, INT-0146, CO11, NCT00002575

Trial Description


RATIONALE: Less invasive types of surgery may help reduce the number of side effects and improve recovery. It is not yet known which type of surgery is more effective for colon cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of laparoscopic-assisted colectomy with open colectomy in treating patients who have colon cancer.

Further Study Information


  • Compare the disease-free and overall survival rates of patients with colon cancer treated with laparoscopic-assisted colectomy vs open colectomy.
  • Compare the safety of these regimens in terms of early and late morbidity and 30-day mortality of these patients.
  • Compare the differences in costs and cost effectiveness between these treatments in this patient population.
  • Compare the differences in quality of life of patients treated with these regimens. (closed as of 4/30/99)

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, primary surgeon, site of primary tumor (right vs left vs sigmoid), and American Society of Anesthesiologists disease classification (I and II vs III). Patients are randomized to one of two treatment arms.

The extent of colon resection is identical for both arms.

  • Arm I: Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.
  • Arm II: Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.

Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.

Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)

Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years.

PROJECTED ACCRUAL: A total of 810 patients will be accrued for this study within 3 years.

Eligibility Criteria


  • Clinical diagnosis of primary adenocarcinoma
  • Involving a single colon segment:
  • Right colon from the ileocecal valve up to and including the hepatic flexure
  • Left colon from the splenic flexure to the junction of the sigmoid and descending colon
  • Sigmoid colon between the descending colon and the rectum (at least 15 cm from the dentate)
  • Diagnosis based on physical exam plus either a proctosigmoidoscopy and barium enema or a colonoscopy
  • No advanced local disease that renders laparoscopic resection impossible
  • No acutely obstructed or perforated colon cancer requiring urgent surgery
  • No transverse colon cancer (i.e., between distal hepatic flexure and proximal splenic flexure)
  • No stage IV disease
  • No rectal cancer (i.e., below the peritoneal reflection, lower edge of tumor less than 15 cm from dentate)
  • No American Society of Anesthesiologists IV/V disease classification
  • No associated gastrointestinal diseases (i.e., Crohn's, chronic ulcerative colitis, or familial polyposis) that require additional extensive operative evaluation or intervention



  • 18 and over

Performance status:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No other prior or concurrent malignancy within the past 5 years except superficial squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Not specified


  • Not specified


  • See Disease Characteristics
  • No prohibitive scars/adhesions from prior abdominal surgery


  • No concurrent investigational treatments or invasive diagnostic procedures within 30 days after surgery

Trial Contact Information

Trial Lead Organizations/Sponsors

North Central Cancer Treatment Group

  • National Cancer Institute
  • Southwest Oncology Group
  • Eastern Cooperative Oncology Group
  • Radiation Therapy Oncology Group
  • Cancer and Leukemia Group B
  • NCIC-Clinical Trials Group
  • National Surgical Adjuvant Breast and Bowel Project
Heidi Nelson, Study Chair
Robert W. Beart, MD, Study Chair
Mark S. Talamonti, Study Chair
John M. Skibber, Study Chair
Jane C. Weeks, Study Chair
Hartley Samuel Stern, Study Chair
Thomas B. Julian, Study Chair

Link to the current record.
NLM Identifier NCT00002575 processed this data on February 27, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to